October 22, 2016 11:14 PM ET


Company Overview of Chimerix, Inc.

Company Overview

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States. The company’s lead product candidate is brincidofovir (CMX001), a nucleotide analog, which is in Phase III clinical trials for the prevention of cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant (HCT) recipients and in kidney transplant recipients, as well as to treat adenovirus infection in allogeneic HCT patients. It is also developing CMX157, a nucleotide analog that is in Phase II clinical stage for the treatment of HIV and hepatitis B virus infection. The company’s preclinical testing product comprises CMX669, a co...

2505 Meridian Parkway

Suite 100

Durham, NC 27713

United States

Founded in 2000

91 Employees





Key Executives for Chimerix, Inc.

Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $505.7K
Chief Financial Officer, Senior Vice President and Corporate Secretary
Age: 58
Total Annual Compensation: $332.5K
Chief Medical Officer
Age: 47
Total Annual Compensation: $493.0K
Chief Commercial Officer
Age: 52
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2015.

Chimerix, Inc. Key Developments

Chimerix, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-12-2016 04:15 PM

Chimerix, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-12-2016 04:15 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: M. Michelle Berrey, Chief Executive Officer, President and Director.

Chimerix, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016

Chimerix, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported net loss decreased to $18.1 million or $0.39 per basic and diluted share compared to a net loss of $24.8 million or $0.59 per basic and diluted share a year ago. Revenues decreased to $1.8 million compared to $4.1 million a year ago. Loss from operations was $18.5 million compared to a loss from operations of $25.0 million for a year ago. The decreased loss was primarily due to lower research and development expenses, and general and administrative expenses. For the six months, the company reported revenues of $3.069 million against $5.381 million a year ago. Net loss was $44.408 million or $0.96 per basic and diluted share against $47.080 million or $1.13 per basic and diluted share a year ago. Loss from operations was $45.157 million against $47.279 million a year ago.

Chimerix, Inc. to Report Q2, 2016 Results on Aug 08, 2016

Chimerix, Inc. announced that they will report Q2, 2016 results at 12:00 PM, GMT Standard Time on Aug 08, 2016

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Chimerix, Inc., please visit www.chimerix.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.